OTLK Resubmits Biologics License Application for ONS-5010/LYTENAVA™, Expects PDUFA Decision Within 60 Days
Outlook Therapeutics, Inc. Common Stock · Now $0.73
+4.2% in 1h after detection
Post-detection moves
1h
+4.2%
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS